Contact:

David K. Waldman/John W. Heilshorn	The Quigley Corporation
Lippert Heilshorn & Associates	Carl Fonash
(212) 838-3777	Shareholder Relations
dwaldman@lhai.com	(267) 880-1111

The Quigley Corporation Receives U.S. Patent for Its Topical Treatment for Radiation Dermatitis

DOYLESTOWN, PA. - July 12, 2004 - The Quigley Corporation (Nasdaq: QGLY) today announced that it has received a patent for QR-335, its topical treatment designed to potentially prevent and relieve the effects of radiation dermatitis. The U.S. Patent, No. 6,753,325 B2 entitled Topical Compositions and Methods for Treatment of Adverse Effects of Ionizing Radiation. A pre-clinical "proof of concept" study on pigskin is currently being planned, since pigs are an established animal model for the testing of likely human skin reactions.

Richard Rosenbloom, M.D., Ph.D., Chief Operating Officer of Quigley Pharma Inc., stated, "This patent provides broad protection for our compound QR-335. The potential market for this product encompasses individuals exposed to radiation for therapeutic purposes such as cancer treatment, diagnostic techniques such as fluoroscopy, or on-the-job exposure. These exposures often cause skin reactions, which range from irritating to severe. If this compound proves successful in preventing radiation dermatitis in a treatment setting, it may also prove valuable in addressing health concerns arising from other, non-medical exposures to radiation."

No claims are made that the compounds discussed herein are safe, effective, or approved by the federal Food and Drug Administration (FDA).

About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer and marketer of diversified health products including the COLD-EEZE® family of patented zinc gluconate glycine (ZIGG™) lozenges and sugar free tablets. COLD-EEZE is the only (ZIGG) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com ), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally-derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the aforementioned products to be studied or marketed.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.